文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于安卡拉改良痘苗病毒疫苗的研发：优势与应用

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications.

作者信息

Orlova Olga Vladimirovna, Glazkova Dina Viktorovna, Bogoslovskaya Elena Vladimirovna, Shipulin German Alexandrovich, Yudin Sergey Mikhailovich

机构信息

Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, 119121 Moscow, Russia.

出版信息

Vaccines (Basel). 2022 Sep 13;10(9):1516. doi: 10.3390/vaccines10091516.

DOI:10.3390/vaccines10091516
PMID:36146594
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9503770/
Abstract

Modified vaccinia virus Ankara (MVA) is a promising viral vector for vaccine development. MVA is well studied and has been widely used for vaccination against smallpox in Germany. This review describes the history of the origin of the virus and its properties as a vaccine, including a high safety profile. In recent years, MVA has found its place as a vector for the creation of vaccines against various diseases. To date, a large number of vaccine candidates based on the MVA vector have already been developed, many of which have been tested in preclinical and clinical studies. We discuss data on the immunogenicity and efficacy of some of these vaccines.

摘要

安卡拉痘苗病毒（MVA）是一种很有前景的用于疫苗开发的病毒载体。MVA已得到充分研究，并在德国被广泛用于天花疫苗接种。本综述描述了该病毒的起源历史及其作为疫苗的特性，包括高度的安全性。近年来，MVA已成为用于研发针对各种疾病疫苗的载体。迄今为止，已经开发了大量基于MVA载体的候选疫苗，其中许多已在临床前和临床研究中进行了测试。我们讨论了其中一些疫苗的免疫原性和效力的数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d5d/9503770/1412c0dbb53b/vaccines-10-01516-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d5d/9503770/1412c0dbb53b/vaccines-10-01516-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d5d/9503770/1412c0dbb53b/vaccines-10-01516-g001.jpg

相似文献

[1]
Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications.

Vaccines (Basel). 2022-9-13

[2]
Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Adv Virus Res. 2017

[3]
Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.

Biomedicines. 2021-11-26

[4]
Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector.

Methods Mol Biol. 2017

[5]
Clinical development of Modified Vaccinia virus Ankara vaccines.

Vaccine. 2013-3-21

[6]
Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus.

Biomedicines. 2021-8-31

[7]
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Virology. 2005-9-1

[8]
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

J Virol. 2018-5-14

[9]
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.

Lancet Infect Dis. 2014-10-30

[10]
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

Expert Rev Vaccines. 2009-4

引用本文的文献

[1]
ISG15 as a Potent Immune Adjuvant in MVA-Based Vaccines Against Zika Virus and SARS-CoV-2.

Vaccines (Basel). 2025-6-27

[2]
Research advances in replication-deficient viral vector vaccines.

Front Vet Sci. 2025-3-3

[3]
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans.

Vaccines (Basel). 2024-11-24

[4]
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.

NPJ Vaccines. 2024-12-23

[5]
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.

Front Immunol. 2024

[6]
A Novel Monoclonal Antibody Against a Modified Vaccinia Ankara (MVA) Envelope Protein as a Tool for MVA Virus Titration by Flow Cytometry.

Viruses. 2024-10-17

[7]
Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice.

Front Immunol. 2024

[8]
Revolutionizing Veterinary Health with Viral Vector-Based Vaccines.

Indian J Microbiol. 2024-9

[9]
Viral Vector-Based Vaccines Encoding CTH522 Induce Distinct Immune Responses in C57BL/6J and HLA Transgenic Mice.

Vaccines (Basel). 2024-8-22

[10]
Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.

Front Immunol. 2024

本文引用的文献

[1]
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.

Proc Natl Acad Sci U S A. 2022-6-14

[2]
Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.

MMWR Morb Mortal Wkly Rep. 2022-6-3

[3]
Development of a Universal Epitope-Based Influenza Vaccine and Evaluation of Its Effectiveness in Mice.

Vaccines (Basel). 2022-3-29

[4]
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.

NPJ Vaccines. 2022-1-21

[5]
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.

PLoS Med. 2022-1

[6]
Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.

Biomedicines. 2021-11-26

[7]
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.

Front Immunol. 2021

[8]
Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies.

NPJ Vaccines. 2021-11-29

[9]
Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.

Front Immunol. 2021

[10]
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.

Nat Commun. 2020-11-30

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索